Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Whiteley, Alex Titomirov & David Lowe

Premium

InforMax, the Bethesda, Md., maker of the GenoMax enterprise bioinformatics system, has appointed Andrew Whiteley as its new chairman, chief executive officer and president. Whiteley, who will assume his duties on April 1, comes to InforMax from Amersham Biosciences, where he most recently served as vice president of bioinformatics. Whiteley also held positions as vice president of Amersham’s sequencing business, and site director of Amersham International PLC’s Cleveland facility. Whiteley holds bachelor’s degrees in chemistry and biochemistry from the UK’s Nottingham University.

This announcement follows a five-month search to replace InforMax founder and CEO Alex Titomirov, who first announced last October he would be stepping down to pursue other interests. While Titomirov stayed on during this transition, he has now resigned from the InforMax board.

 

Amplification startup NuGen Technologies of San Carlos, Calif., has appointed David Lowe to its advisory board. Lowe, who is currently the recipient of a Ewing Marion Kauffman fellowship in venture capital and entrepreneurship, previously held R&D positions at Genentech for 16 years, including a term as director of cardiovascular research. Lowe is a co-inventor of a drug currently in clinical trials, and developed a quantitative real-time PCR method that is now widely used. NuGen, which recently raised $10.8 million in a Series B round of financing, is marketing its Single Primer Isothermal Amplification (SPIA) technology.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.